Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

• Revenue in USD (TTM)0.00
• Net income in USD-8.41m
• Incorporated1986
• Employees4.00

• Location
  Quoin Pharmaceuticals Ltd23 Hata'as StreetKFAR SABA 44425IsraelISR
• Phone+972 99741444
• Fax+972 97678750
• Websitehttps://quoinpharma.com/